• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Capstone Holding Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    1/28/26 7:30:55 AM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CAPS alert in real time by email
    false 0000887151 0000887151 2026-01-28 2026-01-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF

    THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): January 28, 2026

     

    CAPSTONE HOLDING CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-33560   86-0585310
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification No.)

     

    5141 W. 122nd Street

    Alsip, IL 60803

    (Address of principal executive offices)

     

    Registrant’s telephone number, including area code: (708) 371-0660

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which
    registered
    Common Stock, par value $0.0005 per share   CAPS   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 7.01 Regulation FD Disclosure

     

    On January 28, 2026, Capstone Holding Corp. (the “Company”) prepared, published, and distributed a FAQ document regarding questions received from its investors on the Company's Investor Relations website. A copy of such document is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    The information set forth in Item 7.01, including Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language contained in such filing, except as expressly set forth by specific reference in such a filing.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit
    Number
      Exhibits
    99.1   Capstone Holding Corp. FAQ
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    1 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: January 28, 2026 Capstone Holding Corp.
         
      By: /s/ Matthew E. Lipman
      Name:  Matthew E. Lipman
      Title: Chief Executive Officer

     

     

    2

     

    Get the next $CAPS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAPS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CAPS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Capstone Announces Investor FAQ Focused on 2026 Guidance and Earnings

    Company invites shareholder submissions; FAQ to expand on growth trajectory, margin profile, and path to profitability Capstone Holding Corp. (NASDAQ:CAPS), a tech-enabled building products distribution platform, will publish an investor FAQ during the week of May 4, addressing key questions from its shareholder base. The FAQ will provide additional detail on the Company's recent earnings and 2026 guidance, which includes 54% revenue growth and approximately 4x EBITDA growth. Ahead of publication, Capstone is inviting shareholders to submit questions by emailing [email protected]. Submissions will be reviewed by the Company's leadership team, with a selection of response

    4/21/26 7:30:00 AM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capstone Reports FY2025 Results and Guides to 54% Revenue Growth and 4x EBITDA Growth in 2026

    FY2025 gross margin expands to 23% on $46.9M revenue; FY2026 guidance calls for $72.1M of revenue, ~$18.7M of gross profit (+73%), and a positive EBITDA run-rate starting in Q2 Capstone Holding Corp. (NASDAQ:CAPS), a tech-enabled building products distribution platform, today announced financial and operating results for the fourth quarter and full year ended December 31, 2025. The Company closed FY2025 with ~$46.9 million in revenue and gross margin expanding to 23.0%, reflecting acquisition-driven scale and a higher-margin product mix. For FY2026, Capstone expects revenue to rise 54% to $72.1 million, gross margin to reach 26%, and EBITDA to increase more than fourfold to approximatel

    4/16/26 7:30:00 AM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capstone Awarded Eldorado Stone Distribution, Targeting $5 Million in Organic Revenue Growth

    $5 million in organic revenue sold through existing distribution channels with no incremental investment; share-of-wallet capture from existing customers accelerates near-term revenue ramp Capstone Holding Corp. (NASDAQ:CAPS), a tech-enabled building products distribution platform, today announced it has been awarded distribution rights for Eldorado Stone, a premium manufactured stone veneer brand from Westlake Royal Building Products. The Company expects the addition will contribute $5 million in annualized run-rate revenue by Q3 2027, sold entirely through Capstone's existing distribution channels with no incremental infrastructure investment. Capstone is already a top-three national

    4/6/26 7:30:00 AM ET
    $CAPS
    $WLK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Chemicals
    Industrials

    $CAPS
    SEC Filings

    View All

    Amendment: SEC Form 10-K/A filed by Capstone Holding Corp.

    10-K/A - Capstone Holding Corp. (0000887151) (Filer)

    4/17/26 5:15:36 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 10-K/A filed by Capstone Holding Corp.

    10-K/A - Capstone Holding Corp. (0000887151) (Filer)

    4/17/26 4:10:39 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capstone Holding Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Capstone Holding Corp. (0000887151) (Filer)

    4/16/26 3:09:28 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Schultz Edward Christopher

    4 - Capstone Holding Corp. (0000887151) (Issuer)

    4/1/26 6:42:32 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Lipman Matthew E.

    4 - Capstone Holding Corp. (0000887151) (Issuer)

    4/1/26 6:41:21 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Toporek Michael

    4 - Capstone Holding Corp. (0000887151) (Issuer)

    4/1/26 6:40:16 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care